Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow, including Immatics’ ACTengine, ACTallo and TCER bispecific TCR molecule development.
The new Request Management System has made our overall biologics R&D process much more efficient – intergroup communication is now standardized, streamlined and traceable, and there is much less ad hoc communication.
We determined that Genedata Biologics was the best solution to fully address all our unique workflow requirements as it enables scale up of the screening, engineering, production and testing of complex multi-specific antibody candidates.
We have been looking for a workflow system that enables us to scale-up the throughput of our discovery programmes and addresses the large number of bispecific antibodies generated through our proprietary technology platform.
Genedata Biologics is the leading workflow platform for increasing the efficiency of gene therapy R&D, supporting diverse viral delivery systems including adeno-associated virus (AAV), adenovirus, and retrovirus vectors. The platform covers the entire gene therapy workflow, from serotype optimization and viral vector design to virus packaging, purification, and testing. It tracks all samples and associated information including customized vectors and packaging plasmids, cell lysates, purified virus batches and their sequences, titers, and assay results such as empty-to-full capsid ratios. Genedata Biologics provides valuable, real-time insights leading to improved quality control, assay standardization, and more accurate viral potency assessments, putting all critical decision factors in one place to facilitate scale-up and reproducibility during vector manufacturing.